CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Rifampin 600 MGdrug
Likely dose
Rifampin 600 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04463680
NCT04463680Phase 4Completed
CompareCT.gov

The Effect of Rifampin on Etonogestrel Concentrations in Contraceptive Implant Users

University of Colorado, Denver·interventional·Posted Jul 9, 2020·Updated May 16, 2023

In Brief

A Phase 4 clinical trial evaluating Rifampin 600 MG for Contraception and Tuberculosis. Completed, enrolled 24 participants across 1 site.

Detailed Summary

It is important for women taking rifampin to be aware if they are at greater risk of an unintended pregnancy while on the implant. An unintended pregnancy has many social, emotional, and financial impacts on women and society. Rifampin is also a Class C medication for pregnancy and could have potential negative effects on a developing fetus. Additionally, women considering rifampin for treatment of LTBI face additional risks with an unintended pregnancy, making the reliability of contraception even more important for these women. The results of this study can directly inform counseling on a national and international basis for women who use the contraceptive implant and are considering their treatment options for LTBI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception, Tuberculosis
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJul 9, 2020
Enrollment StartSep 23, 2020
Primary CompletionFeb 22, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.0 years ago

Interventions

Rifampin 600 MGdrug

Administered daily for 2 weeks